ABEO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AB

Mkt Cap

$253.6M

Volume

728.87K

Next Earnings

November 11th

Loading chart

AB

ABEOAbeona Therapeutics Inc. Common Stock

ABEO

Pay with—

Available Balance0.00

AB

Mkt Cap

$265.9M

Volume

728.87K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPomerantz LLP is investigating potential securities fraud claims against Abeona Therapeutics following the company's August 13, 2026 disclosure that only four of five patient treatments with ZEVASKYN were recognized for revenue due to one batch lacking minimum sheet requirements. The announcement triggered a 14.95% stock price decline.GlobeNewswire Inc. · Oct 6, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPomerantz LLP announced investigations into potential securities fraud at Abeona Therapeutics following disclosure that only 4 of 5 ZEVASKYN treatments were recognized for revenue due to one batch lacking minimum sheet requirements. The stock fell 14.95% to $6.35 on August 13, 2026. Similar investigations were initiated for JinkoSolar and Stitch Fix.GlobeNewswire Inc. · Sep 29, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Babcock & Wilcox Enterprises, Inc. of Class Action Lawsuit - BWPomerantz Law Firm has filed class action lawsuits against Babcock & Wilcox Enterprises, Inc. (BW) on behalf of investors who acquired securities between November 5, 2025, and March 11, 2026. The firm is also investigating claims on behalf of investors in Abeona Therapeutics Inc. (ABEO) and has announced a class action lawsuit against AST SpaceMobile, Inc. (ASTS) and certain officers.GlobeNewswire Inc. · Sep 15, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Abeona Therapeutics Inc. (Nasdaq: ABEO) granted restricted stock equity awards to five new non-executive employees on June 30, 2026, totaling up to 9,000 restricted shares as a material inducement to employment. The shares will vest over three years with one-third vesting annually, subject to continued employment.GlobeNewswire Inc. · Jul 1, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Abeona Therapeutics Inc. announced the grant of restricted stock equity awards to seven new employees on December 30, 2025, totaling up to 79,584 restricted shares. The awards vest over three years subject to continued employment. The grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducement to employment.GlobeNewswire Inc. · Dec 31, 2025

Here's Why Abeona Therapeutics Popped Higher TodayAbeona Therapeutics saw a significant stock surge of over 25% after reporting strong Q3 earnings and positive updates on Zevaskyn, its gene therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with major insurers now covering the treatment.The Motley Fool · Nov 12, 2025

Trends & Growth Strategies in the $13.5 Billion Cancer Gene Therapy Market 2025-2030 - Advancements CRISPR and CAR-T Solutions Propel Industry GrowthThe global cancer gene therapy market is projected to grow from $4.52 billion in 2024 to $13.58 billion by 2030, driven by rising cancer incidences, advancements in personalized medicine, and innovative gene therapy technologies like CRISPR and CAR-T solutions.GlobeNewswire Inc. · Sep 2, 2025

AscellaHealth Ranks No. 535 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private CompaniesAscellaHealth has been ranked No. 535 on the Inc. 5000 list of fastest-growing private companies, highlighting its success in the specialty pharmaceutical industry through strategic acquisitions and innovative patient support services.GlobeNewswire Inc. · Aug 12, 2025

US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030The report provides detailed insights into the US orphan drug market, highlighting the significant growth opportunity of over $190 billion by 2030. It covers over 1,400 FDA-designated orphan drugs, including their clinical trials, pricing, dosage, and sales data.GlobeNewswire Inc. · May 14, 2025

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)The U.S. FDA has approved ZEVASKYN, the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application.GlobeNewswire Inc. · Apr 29, 2025

to start trading

AB

ABEOAbeona Therapeutics Inc. Common Stock

ABEO

Pay with—

Available Balance0.00

Your PositionYou don't own any ABEO yet.

Related Tickers

Earnings